Abstract
The discontinuation of oral contraceptive use at the time of diagnosis of systemic lupus erythematosus (SLE) has been the usual practice in patients enrolled in the Hopkins Lupus Cohort. The evidence in the literature of a deleterious effect of combined oral contraceptives upon the activity of SLE or on thromboembolism (TE) in SLE is reviewed together with an examination of the potential beneficial effects of oral contraceptives, including better contraception, the control of cyclic SLE disease activity, prevention of osteoporosis, and the preservation of fertility during cyclophosphamide treatment. It is argued that while SLE is a hormonally-driven disease, multiple hormones, and not just estrogen, play a role. Estrogen use as both combined oral contraceptives and for hormone replacement therapy has not been systematically studied, so no quantification of risk and no identification of high-risk groups can be made.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
